Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc. (ESTA)

Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
92. 58
+0.28
+0.3034%
$
2.55B Market Cap
- P/E Ratio
- Div Yield
464,500 Volume
-3.17 Eps
$ 92.3
Previous Close
Add Transaction
Day Range
89.59 92.86
Year Range
33.35 93.12
Want to track ESTA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ESTA closed yesterday higher at $92.58, an increase of 0.3034% from Thursday's close, completing a monthly increase of 31.2075% or $22.02. Over the past 12 months, ESTA stock gained 25.771%.
ESTA is not paying dividends to its shareholders.
The last earnings report, released on May 05, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.2243%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

ESTA Chart

People also search for

Corcept Therapeutics Incorporated
$ 90.52
+0.8917%
TG Therapeutics, Inc.
$ 54.87
-0.1092%
Cerevel Therapeutics Holdings, Inc.
$ 44.96
+0.7394%
Liquidia Corporation
$ 79.94
+6.2043%
Belite Bio, Inc.
$ 150.08
-0.3916%
Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.7 per share a year ago.

Zacks | 2 months ago
Establishment Labs Insider Sells 37,500 Shares as Stock Jumps 128% in a Year

Establishment Labs Insider Sells 37,500 Shares as Stock Jumps 128% in a Year

37,500 shares were sold indirectly for a total transaction value of approximately $2.45 million on April 14, 2026. All shares sold were indirectly held via Sariel Group Ltd, with no direct shares sold; after the trade, the insider retains 45,193 direct shares and 1,182,504 indirect shares, per the Form 4.

Fool | 2 months ago

Establishment Labs Holdings Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
CE
Curtis Ellergodt Rothschild Investment LLC
1 $73 $89.43 $16.43 22.51%
PER
Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc.
21,600 $1.02M $1.93M $916,916.65 90.11%
JD
Jim Dushek HARBOUR INVESTMENTS Inc.
80 $5,347.4 $7,162.38 $1,814.98 33.94%
Joseph Castro
Joseph Castro Nuveen LLC
322,675 $14.4M $28.94M $14.54M 100.94%
MPM
Mark P. Mennitt CenterBook Partners LP
134,973 $6.88M $12.08M $5.2M 75.51%

Establishment Labs Holdings Inc. (ESTA) FAQ

What is the stock price today?

The current price is $92.58.

On which exchange is it traded?

Establishment Labs Holdings Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ESTA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.55B.

Has Establishment Labs Holdings Inc. ever had a stock split?

No, there has never been a stock split.

Establishment Labs Holdings Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Fillipo Peter Caldini CEO
NASDAQ (CM) Exchange
G31249108 CUSIP
US Country
1,004 Employees
- Last Dividend
- Last Split
19 Jul 2018 IPO Date

Overview

Establishment Labs Holdings Inc. is a prominent medical technology company that has carved a niche for itself in the realm of aesthetic and reconstructive plastic surgery. Having been incorporated in 2004, the company is headquartered in Alajuela, Costa Rica. Over the years, Establishment Labs has dedicated itself to the manufacture and marketing of high-quality medical devices, focusing predominantly on innovations within the breast implant sector. Its products, underpinned by advanced technology, are designed to cater to the diverse needs of patients worldwide, aiming to enhance both aesthetic appeal and comfort. The company leverages a robust network of distributors and direct sales forces to deliver its solutions to physicians, hospitals, and clinics across key regions including Europe, the Middle East, Latin America, and Asia, thereby securing a significant position in the global medical aesthetic market.

Products and Services

  • Motiva Implants
  • The flagship products of Establishment Labs, Motiva Implants, represent a line of silicone gel-filled breast implants renowned for their superior design and safety profiles. These implants are engineered to meet the varied aesthetic and reconstructive needs of patients, encapsulating the company's commitment to innovation and patient satisfaction.

  • Motiva Ergonomix and Motiva Ergonomix2
  • Motiva Ergonomix and Motiva Ergonomix2 are specifically designed to mimic the natural movement of breast tissue, offering a gravity-sensitive option within the silicone gel-filled breast implants category. These products demonstrate Establishment Labs’ prowess in creating implants that provide a natural look and feel, thereby enhancing patient outcomes and comfort.

  • Motiva Flora Tissue Expander
  • The Motiva Flora Tissue Expander is a surgical device intended for use in breast reconstruction procedures. It enables the gradual expansion of breast tissue, facilitating the subsequent insertion of a breast implant. This product underscores Establishment Labs’ contribution to the field of reconstructive surgery, offering innovative solutions that support patient recovery and aesthetic reconstruction.

Contact Information

Address: 11401 century oaks terrace
Phone: 506 2434 2400